NeuroSearch, Glaxo start Phase II studies of NS2359 depression
Forbes - COPENHAGEN (AFX) - NeuroSearch AS said it and GlaxoSmithKline PLC (GSK) have started Phase II clinical development of drug candidate NS2359 (GSK372475) in patients diagnosed with major depressive disorder. Under a development and licensing agreement
Source: www.forbes.com
UPDATE 4-Biovail stock up on dividend hike, strategy shift
Reuters - BVF.N: Quote , Profile , Research ) said on Wednesday it plans to triple its dividend, pay off debt and focus on drug development as it readies for copycat drugs that will challenge its main anti-depression treatment. The company will also axe its U.S
Source: today.reuters.com
College depression surveyed
Daily Beacon Online - Men are far less likely to ask for depression treatment. According to mtvU officials, these numbers have a lot to say about college students’ thoughts and behavior. “The alarming statistics speak for themselves, showing that students are masking
Source: dailybeacon.utk.edu
Click here for more information about depression in men depression in men
<< Home